Chemotherapy-induced nausea and vomiting (CINV) with carboplatin plus pemetrexed or carboplatin plus paclitaxel in patients with lung cancer: a propensity score-matched analysis
Abstract Background Patients with lung cancer who are treated with carboplatin-based chemotherapy regimens often experience chemotherapy-induced nausea and vomiting (CINV). However, knowledge on the effect of regimen and cofactors on the risk of CINV is limited. This study aimed to analyze and compa...
Main Authors: | , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2021-01-01
|
Series: | BMC Cancer |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12885-021-07802-y |
id |
doaj-e548427c17de46b09da2a79e4f63c8f8 |
---|---|
record_format |
Article |
spelling |
doaj-e548427c17de46b09da2a79e4f63c8f82021-01-17T12:56:50ZengBMCBMC Cancer1471-24072021-01-012111910.1186/s12885-021-07802-yChemotherapy-induced nausea and vomiting (CINV) with carboplatin plus pemetrexed or carboplatin plus paclitaxel in patients with lung cancer: a propensity score-matched analysisToshinobu Hayashi0Mototsugu Shimokawa1Koichi Matsuo2Hirotoshi Iihara3Kei Kawada4Takafumi Nakano5Takashi Egawa6Department of Pharmaceutical and Health Care Management, Faculty of Pharmaceutical Sciences, Fukuoka UniversityDepartment of Biostatistics, Yamaguchi University Graduate School of MedicineDepartment of Pharmaceutical and Health Care Management, Faculty of Pharmaceutical Sciences, Fukuoka UniversityDepartment of Pharmacy, Gifu University HospitalDepartment of Pharmacy, Kochi Medical School HospitalDepartment of Pharmaceutical and Health Care Management, Faculty of Pharmaceutical Sciences, Fukuoka UniversityDepartment of Pharmaceutical and Health Care Management, Faculty of Pharmaceutical Sciences, Fukuoka UniversityAbstract Background Patients with lung cancer who are treated with carboplatin-based chemotherapy regimens often experience chemotherapy-induced nausea and vomiting (CINV). However, knowledge on the effect of regimen and cofactors on the risk of CINV is limited. This study aimed to analyze and compare the incidence of CINV between lung cancer patients undergoing carboplatin plus pemetrexed (CBDCA+PEM) and those undergoing carboplatin plus paclitaxel (CBDCA+PTX) chemotherapy. Methods Pooled data of 240 patients from two prospective observational studies were compared using propensity score matching. Separate multivariate logistic regression analyses were used to identify risk factors for nausea and vomiting following chemotherapy. Results Delayed nausea was significantly more common in patients treated with CBDCA+PEM than in those treated with CBDCA+PTX (51.1% vs. 36.2%, P = 0.04), but the incidence of vomiting did not significantly differ between the two groups (23.4% vs. 14.9%, P = 0.14). The occurrence of CINV peaked on day 4 in the CBDCA+PTX group and on day 5 in the CBDCA+PEM group. Multivariate analysis showed that female sex, younger age, and CBDCA+PEM regimen were independent risk factors for delayed nausea, while female sex was an independent risk factor for delayed vomiting. Conclusions The CBDCA + PEM regimen has a higher risk of causing delayed nausea than the CBDCA + PTX regimen, and aggressive antiemetic prophylaxis should be offered to patients treated with CBDCA + PEM.https://doi.org/10.1186/s12885-021-07802-yAntiemeticsChemotherapy-induced nausea and vomitingEmetogenicityLung cancerClassificationCarboplatin |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Toshinobu Hayashi Mototsugu Shimokawa Koichi Matsuo Hirotoshi Iihara Kei Kawada Takafumi Nakano Takashi Egawa |
spellingShingle |
Toshinobu Hayashi Mototsugu Shimokawa Koichi Matsuo Hirotoshi Iihara Kei Kawada Takafumi Nakano Takashi Egawa Chemotherapy-induced nausea and vomiting (CINV) with carboplatin plus pemetrexed or carboplatin plus paclitaxel in patients with lung cancer: a propensity score-matched analysis BMC Cancer Antiemetics Chemotherapy-induced nausea and vomiting Emetogenicity Lung cancer Classification Carboplatin |
author_facet |
Toshinobu Hayashi Mototsugu Shimokawa Koichi Matsuo Hirotoshi Iihara Kei Kawada Takafumi Nakano Takashi Egawa |
author_sort |
Toshinobu Hayashi |
title |
Chemotherapy-induced nausea and vomiting (CINV) with carboplatin plus pemetrexed or carboplatin plus paclitaxel in patients with lung cancer: a propensity score-matched analysis |
title_short |
Chemotherapy-induced nausea and vomiting (CINV) with carboplatin plus pemetrexed or carboplatin plus paclitaxel in patients with lung cancer: a propensity score-matched analysis |
title_full |
Chemotherapy-induced nausea and vomiting (CINV) with carboplatin plus pemetrexed or carboplatin plus paclitaxel in patients with lung cancer: a propensity score-matched analysis |
title_fullStr |
Chemotherapy-induced nausea and vomiting (CINV) with carboplatin plus pemetrexed or carboplatin plus paclitaxel in patients with lung cancer: a propensity score-matched analysis |
title_full_unstemmed |
Chemotherapy-induced nausea and vomiting (CINV) with carboplatin plus pemetrexed or carboplatin plus paclitaxel in patients with lung cancer: a propensity score-matched analysis |
title_sort |
chemotherapy-induced nausea and vomiting (cinv) with carboplatin plus pemetrexed or carboplatin plus paclitaxel in patients with lung cancer: a propensity score-matched analysis |
publisher |
BMC |
series |
BMC Cancer |
issn |
1471-2407 |
publishDate |
2021-01-01 |
description |
Abstract Background Patients with lung cancer who are treated with carboplatin-based chemotherapy regimens often experience chemotherapy-induced nausea and vomiting (CINV). However, knowledge on the effect of regimen and cofactors on the risk of CINV is limited. This study aimed to analyze and compare the incidence of CINV between lung cancer patients undergoing carboplatin plus pemetrexed (CBDCA+PEM) and those undergoing carboplatin plus paclitaxel (CBDCA+PTX) chemotherapy. Methods Pooled data of 240 patients from two prospective observational studies were compared using propensity score matching. Separate multivariate logistic regression analyses were used to identify risk factors for nausea and vomiting following chemotherapy. Results Delayed nausea was significantly more common in patients treated with CBDCA+PEM than in those treated with CBDCA+PTX (51.1% vs. 36.2%, P = 0.04), but the incidence of vomiting did not significantly differ between the two groups (23.4% vs. 14.9%, P = 0.14). The occurrence of CINV peaked on day 4 in the CBDCA+PTX group and on day 5 in the CBDCA+PEM group. Multivariate analysis showed that female sex, younger age, and CBDCA+PEM regimen were independent risk factors for delayed nausea, while female sex was an independent risk factor for delayed vomiting. Conclusions The CBDCA + PEM regimen has a higher risk of causing delayed nausea than the CBDCA + PTX regimen, and aggressive antiemetic prophylaxis should be offered to patients treated with CBDCA + PEM. |
topic |
Antiemetics Chemotherapy-induced nausea and vomiting Emetogenicity Lung cancer Classification Carboplatin |
url |
https://doi.org/10.1186/s12885-021-07802-y |
work_keys_str_mv |
AT toshinobuhayashi chemotherapyinducednauseaandvomitingcinvwithcarboplatinpluspemetrexedorcarboplatinpluspaclitaxelinpatientswithlungcancerapropensityscorematchedanalysis AT mototsugushimokawa chemotherapyinducednauseaandvomitingcinvwithcarboplatinpluspemetrexedorcarboplatinpluspaclitaxelinpatientswithlungcancerapropensityscorematchedanalysis AT koichimatsuo chemotherapyinducednauseaandvomitingcinvwithcarboplatinpluspemetrexedorcarboplatinpluspaclitaxelinpatientswithlungcancerapropensityscorematchedanalysis AT hirotoshiiihara chemotherapyinducednauseaandvomitingcinvwithcarboplatinpluspemetrexedorcarboplatinpluspaclitaxelinpatientswithlungcancerapropensityscorematchedanalysis AT keikawada chemotherapyinducednauseaandvomitingcinvwithcarboplatinpluspemetrexedorcarboplatinpluspaclitaxelinpatientswithlungcancerapropensityscorematchedanalysis AT takafuminakano chemotherapyinducednauseaandvomitingcinvwithcarboplatinpluspemetrexedorcarboplatinpluspaclitaxelinpatientswithlungcancerapropensityscorematchedanalysis AT takashiegawa chemotherapyinducednauseaandvomitingcinvwithcarboplatinpluspemetrexedorcarboplatinpluspaclitaxelinpatientswithlungcancerapropensityscorematchedanalysis |
_version_ |
1724334213968166912 |